---
layout: post
title: "Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications"
date: 2026-02-04 21:49:24 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-18453
original_published: 2025-09-24 00:00:00 +0000
significance: 8.00
---

# Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 24, 2025 00:00 UTC
**Document Number:** 2025-18453

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/24/2025-18453/elite-laboratories-inc-et-al-withdrawal-of-approval-of-72-abbreviated-new-drug-applications)
- API: https://www.federalregister.gov/api/v1/documents/2025-18453

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
